A Phase 1 Open-Label, Dose-Escalation Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2018
At a glance
- Drugs INCB 59872 (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Incyte Corporation
- 24 Oct 2018 Status changed from recruiting to discontinued due to a business decision not to pursue INCB059782 in Sickle Cell Disease indication.
- 15 Jan 2018 Planned End Date changed from 1 Jun 2018 to 1 Sep 2018.
- 15 Jan 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Sep 2018.